Share Name Share Symbol Market Type Share ISIN Share Description
Mercia Technolgies PLC LSE:MERC London Ordinary Share GB00BSL71W47 ORD 0.001P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 36.20p 35.40p 37.00p 36.20p 36.20p 36.20p 94,315 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Support Services 10.2 1.6 0.6 65.8 109.80

Mercia Technolgies Share Discussion Threads

Showing 276 to 298 of 300 messages
Chat Pages: 12  11  10  9  8  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
21/9/2018
07:34
AGM statement: "We are seeing an increasing number of exciting investment opportunities for Mercia's third-party managed funds which will, in due course, lead to further balance sheet direct investment opportunities." "Our focus remains on growing the net asset value of the Group's direct investments by utilising Mercia's differentiated model to create long term value for shareholders. We look forward to updating shareholders on further positive progress throughout the year."
aishah
18/9/2018
12:16
Nice contract news flow recently. nDreams, Oxford Genetics and now Aston EyeTech
aishah
18/9/2018
09:23
A re-rating appears to be underway, and further positive portfolio news has been indicated. One would also imagine that the portfolio companies presenting and providing interviews at the Capital Market Day, also have good things to report.
wan
18/9/2018
07:43
Well timed increase in holding AISHAH :-) excellent news this morning
cheshire man
18/9/2018
07:36
Aston EyeTech secures a significant multi-million pound contract Mercia Technologies PLC (AIM: MERC), the national investment group focused on the identification, creation, funding and scaling of innovative technology businesses with high-growth potential from the UK regions, is pleased to announce that Aston EyeTech Limited ("Aston EyeTech") has secured a multi-million pound product design, development and manufacturing contract with one of the largest, most successful and fastest growing optical retailers in the world. Aston EyeTech is revolutionising the eyecare industry through increased portability, wider accessibility, lower costs and better user experiences. The company marries game-changing ophthalmic hardware with its proprietary AI software platforms to provide leading edge technology solutions in the optical space. Mercia, which holds an 18.7% direct equity stake in the business and has worked with Aston EyeTech since 2013, initially invested via its third-party managed funds before making its first direct investment in November 2017. In addition to this major contract win, over the last 12 months the business has launched its new EYOTO™ brand of power-mapping lens visualizers. Dr Mark Payton, Chief Executive Officer of Mercia Technologies, said: "Aston EyeTech is another good example of our promising direct investment portfolio, many of which are now in revenue growth. I expect more positive developments from this business and a number of our other direct investments in the near to medium term, as the portfolio continues to mature."
aishah
14/9/2018
12:57
Happy to have doubled up here few weeks ago.
aishah
14/9/2018
12:40
Recovering well from recent lows.
weatherman
13/9/2018
08:10
Welcome to my world ;-)
wan
13/9/2018
07:55
Hope springs eternal, but I live in the real world.
redartbmud
13/9/2018
07:28
Today's news regarding the Capital Markets Day should provide institutions, analysts and private investors with some interesting insights, which might create buying interest. Let's also hope we get further positive portfolio news between now and then (which would help focus the minds of those attending) and the recent low in share price proves to have been the bottom!
wan
29/8/2018
09:01
Mercia Technologies PLC (AIM: MERC), the national investment group focused on the identification, creation, funding and scaling of innovative technology businesses with high growth potential from the UK regions, announces that options (the "Options") over a total of 4,689,000 new Ordinary shares with a nominal value of 0.001p each in the capital of the Company ("Ordinary Shares") were awarded yesterday pursuant to the 2014 Mercia Company Share Option Plan at an exercise price of 30.80p per Ordinary Share (being the closing mid-market price of an Ordinary Share on 28 August 2018). The Options will, subject to the satisfaction of the performance condition, vest in three equal tranches on the third, fourth and fifth anniversary of the date of grant of the Options. Snout in trough. The 56p options will never vest, so this is a gimme.
redartbmud
29/8/2018
07:42
"Following these grants, the Company has a total of 14,851,000 unvested options pursuant to the 2014 Mercia Company Share Option Plan, equating to approximately 4.90% of the existing issued Ordinary share capital of the Company."
p1nkfish
29/8/2018
07:41
More options Anyone know if same criteria as recent options - so about 56p? >4% of co now in options if I remember right. share price prformance lacking.
p1nkfish
24/8/2018
11:17
Indeed - the multi-million-£ contract announcement was also the reason I bought back-in... look forward to further announcements...
livewireplus
24/8/2018
11:06
It was on the 8th following the Oxford Genetics multi-million pound contract. Techinvest are also positive and added more to their portfolio in July.
aishah
24/8/2018
10:50
That was good timing then .... unusually I also had good timing with this - sold out in upper 30's earlier in year but then back in at upper 20's recently. Look forward to a rise in to the 40's again... unless Mr. Trump precipitates a World Wide recession...
livewireplus
24/8/2018
10:06
Doubled my holding earlier this month.
aishah
16/8/2018
07:55
With the shares languishing at new lows, today's news is again welcome, but does it provide a catalyst for a change in share price direction? I note Mercia expect to announce further positive news from their direct investment portfolio. I note a further recent investment by Mercia (and others). Another recent successful fund raise also highlights the level of interest in AI in healthcare - Intelligent healthcare company Rinicare announces completion of financing Rinicare raises money to support the commercialisation of its digital healthcare portfolio Manchester, UK, 15th August 2018 - Rinicare Limited, a leading intelligent healthcare company has announced the completion of its financing round by welcoming new investors Catapult Ventures and NPIF - Mercia Equity Finance, which is managed by Mercia Fund Managers and part of the Northern Powerhouse Investment Fund. The funding will be used to support the commercialisation of Rinicare’s digital healthcare portfolio, which is designed to provide solutions that improve outcomes and reduce costs in a number of settings such as emergency, primary and community care as well as progress its AI-powered predictive algorithm for intensive care. Healthcare providers around the world face the challenge of maintaining sustainable healthcare systems in light of an ageing population and continuously increasing costs. Rinicare’s approach to addressing these challenges is based on a collaborative effort with clinicians and end users to design advanced wireless communications, innovative prediction algorithms and enhanced software technology solutions that demonstrably improve outcomes and reduce healthcare costs. The company markets its wireless physiological signs technology (PRIME) and its falls prevention system (SAFE) globally in a number of healthcare solutions, which are tailored to individual needs. In addition to its expanding marketed solutions, Rinicare is developing its AI predictive system, Stability, which is initially focused at intensive care and addresses a global market for predictive healthcare analytics. This fast emerging area of healthcare is estimated to grow at a compound annual growth rate of over 25%, reaching an estimated global market value of $24.6billion by 2022. Stuart Hendry, CEO of Rinicare, commented: “We are very pleased to welcome such high-quality investors in this financing round. We will be using proceeds to support the ongoing commercialisation of our PRIME and SAFE based healthcare solutions in the UK and abroad as well as continuing with the development of world-leading Stability AI intensive care programme that has already captured data from several thousand intensive care patients.” Dr Vijay Barathan, Life Science Partner, Catapult Ventures said: “We are excited to work with Rinicare as they commercialise their intelligent health product portfolio in the UK and international healthcare markets. Each product represents an innovative solution and significant market opportunity.” Dr Mark Wyatt, Investment Director at Mercia, said: “I am looking forward to working with the Rinicare team, and I am excited to see their technologies drive efficiency gains and patient benefits into the healthcare system.” Sue Barnard, Senior Relationship Manager at British Business Bank, said: “The healthcare market is evolving rapidly, and is expected to grow significantly over the next few years. The North is home to many innovative businesses in this space, such as Rinicare, and NPIF is pleased to support those looking to enter the next phase of growth.” The Northern Powerhouse Investment Fund project is supported financially by the European Union using funding from the European Regional Development Fund (ERDF) as part of the European Structural and Investment Funds Growth Programme 2014-2020 and the European Investment Bank. hxxp://www.rinicare.com/news/press-releases/item/48-intelligent-healthcare-company-rinicare-announces-completion-of-financing
wan
07/8/2018
10:18
This should lead to higher NAV in time. MERCs investment in OG is £9m, representing 40 percent of a £22m company - growing revenue rapidly 100% y-o-y according to last statement. OG is approx 7.5% of MERCs stated NAV, but currently trading at a big discount. I would suggest OGs prospects alone point to a rerating. The current discount is an anomaly to the real value.
weatherman
07/8/2018
09:26
p1nk The buyers of the last rights issue, who paid 46p/share, must echo your sentiments.
redartbmud
07/8/2018
08:50
Yes, I may have been a little too negative.
p1nkfish
07/8/2018
08:39
Market likes the news good to see the chart turning, as you pointed out p1nkfish seems we have a lot to look forward to,,,,,
cheshire man
07/8/2018
08:23
Very good OG news. Read last sentence below as hint of more to come from OG and OTHER direct investments. It could still double by Dec 2019. Looks like a Buy if not already and a strong hold imho. "Dr Mark Payton, Chief Executive Officer of Mercia Technologies and a non-executive director of Oxford Genetics, said: "OG is a good example of our promising direct investment portfolio of companies, many of which are now in revenue growth. The company has an extensive intellectual property estate coupled tightly with its global access to CRISPR technology. The growing quality and number of its clients is testament to the fact that the team is at the leading edge of synthetic biology innovation. I expect more positive developments from OG and a number of our OTHER direct investments in the near to medium term.""  
p1nkfish
Chat Pages: 12  11  10  9  8  7  6  5  4  3  2  1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20180924 19:46:32